Rigel Pharmaceuticals RIGL fostamatinib — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
We also have an exclusive license and supply agreement with Kissei entered in October 2018, amended in November 2022, October 2023, August 2024, September 2024 and October 2024, to develop and commercialize fostamatinib in all current and potential indications in related Kissei territory. As of March 31, 2026 and December 31, 2025, the remaining deferred revenue was related to the material right associated with discounted fostamatinib supply which amounted to $1.4 million. During the three months ended March 31, 2025, we recognized $3.0 million of contract revenue from collaborations related to a non-refundable and non-creditable milestone payment from Kissei in connection with the approval of fostamatinib in Korea.
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's fostamatinib — deferred revenue?
- Rigel Pharmaceuticals (RIGL) reported fostamatinib — deferred revenue of $1.4M in Q1 2026.
- How has Rigel Pharmaceuticals's fostamatinib — deferred revenue changed year-over-year?
- Rigel Pharmaceuticals's fostamatinib — deferred revenue decreased by 53.3% year-over-year, from $3M to $1.4M.
- What does fostamatinib — deferred revenue mean?
- Represents the portion of revenue received from customers or partners for the fostamatinib product that has not yet been earned. This liability reflects obligations to provide future goods or services under existing contracts. Monitoring this balance helps investors assess future revenue recognition potential as performance obligations are satisfied.
Ask your AI about Rigel Pharmaceuticals's fostamatinib — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
